PRESS-NEWS.org - Press Release Distribution
PRESS RELEASES DISTRIBUTION

Broad-spectrum coronavirus drug developed through AI-enabled dynamic modeling

Multidisciplinary AI- and physics-driven modeling of the viral fusion process enables discovery of an orally available drug inhibiting infection with multiple coronaviruses

2025-06-12
(Press-News.org)

By Benjamin Boettner

(BOSTON) — About 30% of all respiratory tract infections are caused by coronaviruses, leading to widespread illnesses and, in some cases, to epidemic and even pandemic outbreaks, as we experienced with the COVID-19 pandemic. Despite the development of groundbreaking technology that enables the design of prophylactic vaccines, access to those vaccines is not equal across the globe, especially in low-resource countries, and also other hesitations prevent their adoption. 

In addition, coronavirus variants are emerging that can have higher infectivity and resistance to existing vaccines and antiviral treatments. Therefore, fast-acting antiviral drugs with broad activity against multiple respiratory coronaviruses and the ability to be rapidly distributed as oral treatments are urgently needed. 

In 2020, at the beginning of the COVID-19 pandemic, a multidisciplinary team of computational biologists, and infectious disease, medical chemistry and drug development experts formed at the Wyss Institute for Biologically Inspired Engineering at Harvard University. With early support from the Defense Advanced Research Agency (DARPA), the team, led by Wyss Founding Director Donald Ingber, M.D, Ph.D., sought to leverage the Wyss Institute’s existing computational and biological modeling capabilities to rapidly repurpose existing FDA-approved drugs for the fight against the disease. 

By creating a cohesive AI-enabled and physics-based molecular modeling and drug discovery pipeline built around film industry procedural animation software, they identified the orally available, FDA-approved drug bemcentinib, as a potential antiviral agent. However, to further optimize its activity with follow up support from Open Philanthropy-Good Ventures Foundation, they used this chemical compound as a launch pad for developing a more specific and effective antiviral drug with efficacy against a broad range of coronaviruses. Their findings are published in Frontiers in Molecular Biosciences.

Taking coronaviruses to the movies

During COVID-19, many research groups sought to develop drugs that target the external surfaces of Spike proteins shared by coronaviruses, which bind to receptor molecules on the surface of host cells and mediate virus entry. At the start of the project, the researchers hypothesized that rather than targeting these external sites, which are prone to mutation under the pressure of vaccines and therapies, focusing on hidden regions of the Spike protein could offer unprecedented benefits. “We thought that constant regions that remain hidden while the virus initially binds to its host cell, but become accessible during a critical time window when it prepares itself for membrane fusion could be ideal sites. Targeting those could be a way to essentially lock the virus in at the pre-fusion stage before it can release its genetic material into the cytoplasm of host cells,” said first-author Charles Reilly, Ph.D., a former Wyss Principal Scientist who led the project with Ingber. “The major challenge lay in identifying these moving cogs for which we could design drugs that could work as a universal wrench for multiple coronaviruses.” 

Previously, Reilly and Ingber had used tools from the film special effects industry to develop computational models of how molecules move and function from the atomic level to that of whole cells, and they used this to depict movements during the origins of human life – the fusion of a sperm with an egg cell – as featured in the short film, “The Beginning”. 

The team used a similar approach to model the dynamic transformations that the SARS-CoV-2 Spike protein undergoes after binding its receptor and while literally moving towards fusion. To accomplish this complex modelling, they essentially animated a variety of structural snapshots of the Spike protein that other researchers had captured at different stages of virus binding and fusion in X-Ray crystallography and other studies. This “molecular dynamics simulation,” based on actual physical features of the Spike protein, allowed them to generate “synthetic data” in which they could glean regions in the so-called S2 subunit of the protein that underwent large-scale mechanical transitions. By applying AI methods to their synthetic data, they were able to pinpoint a specific site within one of those mechanically highly-active regions that revealed itself at a pre-fusion step before facilitating the Spike protein’s embedding within the host cell membrane. This key site had potential to function as a binding pocket for drug compounds that would gum up the works to prevent membrane fusion and viral entry and, importantly, it was shared by different members of the coronavirus family. 

Drugging the moving target

To identify drugs that could precisely fit themselves into the predicted binding pocket within the Spike protein’s S2 subunit, the researchers computationally screened through about 10,000 existing drugs and ranked them according to their predicted binding affinities to the pocket. The highest-ranking drug that was also orally available was bemcentinib, which in their AI-enabled simulations and molecular docking studies remained strongly bound across multiple structural changes the entire region was undergoing, eventually freezing it at the pre-fusion stage. In fact, the team, with drug development expertise of Wyss Senior Principal Scientist Sylvie Bernier, Ph.D., and Wyss’ Senior Director, Translational R&D, Ken Carlson, Ph.D., demonstrated that bemcentinib potently inhibited SARS-CoV-2 infection of human lung cells expressing the ACE2 receptor on their surface by preventing its entry into the cells.

Interestingly, the infection-blocking effect of bemcentinib had also been observed by other researchers, and bemcentinib had actually improved clinical outcomes in a clinical trial with hospitalized COVID-19 patients. But it was generally assumed that the drug had to function through its original target, the AXL kinase protein, which helps drive the growth of tumor cells. “To unequivocally prove that bemcentinib achieved its antiviral activity through our proposed mechanism and further improve its efficacy, we needed to create structurally similar compounds (analogs) that lack any affinity to AXL but retain their affinity to the Spike protein’s binding pocket,” said Reilly.

Joel Moore, Ph.D., a talented medicinal chemist on the team, designed a series of novel compounds, the best of which, dubbed WYS-633, inhibited the entry of SARS-CoV-2 viruses into lung cells just like bemcentinib did and, importantly, without binding to AXL. WYS-633 also prevented SARS-CoV-1, MERS, and multiple SARS-CoV-2 variants from infecting cells, suggesting that the approach could indeed lead to a broad-spectrum antiviral drug against multiple coronaviruses. 

To further improve the drug-like features of WYS-633, also with an eye towards oral bioavailability, the team performed another round of medical chemistry, AI-enabled computational analysis, and in vitro testing, which culminated in WYS-694, an antiviral compound 12.5-fold more potent than WYS-633. In a last crucial step, Bernier, Carlson, and other members of the team tested WYS-694 as an oral prophylactic treatment in mice expressing the human ACE2 receptor, which they infected with the SARS-CoV-2 virus.  While both bemcentinib and WYS-633 failed to reduce the viral load, WYS-694 reduced the viral load in the animals by more than 4-fold and significantly inhibited SARS-CoV-2 infection.

“While additional computational predictions using Google’s AlphaFold 3 machine learning algorithm supported our central hypothesis, we will still have to demonstrate that WYS-694 precisely binds to the target site we identified in the Spike protein’s S2 subunit through detailed structural studies, and that the interaction alone and no other potential target enables the antiviral activity,” said Reilly. “But our findings are extremely compelling and open up a new path for dealing with viral outbreaks.”

“By aiming for an orally available drug that broadly inhibits multiple coronaviruses, even as a prophylactic treatment, we deliberately set the bar at maximum height,” said senior author Ingber. “Yet, our integrated approach merging new AI-driven computational and experimental technologies has proven to be incredibly powerful in achieving this goal. Beyond producing a promising new drug that could be useful in future respiratory pandemics, this approach holds great potential for the discovery of drugs against a number of other virus families utilizing membrane fusion proteins, including influenza, HIV, Ebola, Measles, and others.” Ingber is also the Judah Folkman Professor of Vascular Biology at Harvard Medical School and Boston Children’s Hospital and the Hansjörg Wyss Professor of Biologically Inspired Engineering at the Harvard John A. Paulson School of Engineering and Applied Sciences.

Additional authors on the study were Shanda Lightbown and Austin Paul. The study was supported by the Wyss Institute at Harvard University, a contract from the DARPA (under contract #HR0011-20-2-0040), and additional funding by the Open Philanthropy–Good Ventures Foundation and Alfred P. Sloan Foundation.

PRESS CONTACTS

Wyss Institute for Biologically Inspired Engineering at Harvard University
Benjamin Boettner, benjamin.boettner@wyss.harvard.edu

###

The Wyss Institute for Biologically Inspired Engineering at Harvard University (www.wyss.harvard.edu) is a research and development engine for disruptive innovation powered by biologically-inspired engineering with visionary people at its heart. Our mission is to transform healthcare and the environment by developing ground-breaking technologies that emulate the way Nature builds and accelerate their translation into commercial products through formation of startups and corporate partnerships to bring about positive near-term impact in the world. We accomplish this by breaking down the traditional silos of academia and barriers with industry, enabling our world-leading faculty to collaborate creatively across our focus areas of diagnostics, therapeutics, medtech, and sustainability. Our consortium partners encompass the leading academic institutions and hospitals in the Boston area and throughout the world, including Harvard’s Schools of Medicine, Engineering, Arts & Sciences and Design, Beth Israel Deaconess Medical Center, Brigham and Women’s Hospital, Boston Children’s Hospital, Dana–Farber Cancer Institute, Massachusetts General Hospital, the University of Massachusetts Medical School, Spaulding Rehabilitation Hospital, Boston University, Tufts University, Charité – Universitätsmedizin Berlin, University of Zürich, and Massachusetts Institute of Technology.

 

 

END



ELSE PRESS RELEASES FROM THIS DATE:

An explanation for out-of-body experiences

2025-06-12
Out-of-body experiences – where people feel like spirits disconnected from their physical form – may be a coping mechanism triggered by trauma or other overwhelming stress, new University of Virginia School of Medicine research suggests. That idea challenges the common assumption that out-of-body experiences, or OBEs, are solely a symptom of mental illness. Based on data from more than 500 people, the researchers, including UVA Health’s Marina Weiler, PhD, instead argue for a more nuanced perspective: that OBEs may represent an underlying issue that could be a better treatment target than the out-of-body experiences ...

Unprecedented optical clock network lays groundwork for redefining the second

2025-06-12
WASHINGTON — In a new study, researchers carried out the most extensive coordinated comparison of optical clocks to date by operating clocks and the links connecting them simultaneously across six countries. Spanning thousands of kilometers, the experiment represents a significant step toward redefining the second and ultimately establishing a global optical time scale. “The accurate time and frequency signals provided by atomic clocks are essential for many everyday technologies — like GPS, managing power grids and keeping financial transactions in sync,” said  Helen Margolis, head of time and frequency ...

Virginia Tech fog harp gets an upgrade

2025-06-12
A third of the world’s population struggles with water scarcity. In many of these areas, fog holds water that could provide a lifeline — if only it could be captured. Harvesting that water more efficiently has become the work of researchers from two colleges at Virginia Tech, who recently improved on their original fog harp design with a model that more closely resembles another musical instrument: a guitar. Their latest findings have been published by the Royal Society of Chemistry. Harvesting water from resources such as fog is not a new idea. Archaeologists have found evidence of ancient ...

Exposomics: Holistic health without the snake oil

2025-06-12
We live in the age of -omics. We have genomics to study complete sets of DNA. We have proteomics focused on all the proteins within our cells. And we have metabolomics for metabolites like sugars and lipids. Despite their massive reach and intense focus, these fields have blind spots. They’re both in the margins and all around us. Today, we know we’re as much a product of our surroundings as our genetics. The question then becomes, “How do we measure the impacts of all these external factors in conjunction with one another—and with the biology ...

TTUHSC researchers to study gene’s role in prostate cancer metastasis

2025-06-12
The American Cancer Society estimates that more than 313,780 cases of prostate cancer will be diagnosed in the United States in 2025, resulting in approximately 35,770 deaths. Bone metastasis — a stage of prostate cancer where the disease spreads to the bones — is the leading cause of prostate cancer-related death and currently remains incurable. “This stage of prostate cancer is devastating to the patient, as it often affects the bones of the spine, resulting in severe pain from fractures and spinal cord compression, along with significant neurological and functional disabilities,” Srinivas Nandana, Ph.D., ...

Lymph node on a chip: New immune system model may enhance precision medicine research

2025-06-12
Scientists with the Fralin Biomedical Research Institute at VTC have created an engineered model of the supportive tissue found within a lymph node to study human health.   Working with scientists at the University of Virginia, the researchers are building a bioengineered model of a human lymph node, which performs essential roles in the immune system throughout the body.  The goal of the research, which published in April in APL Bioengineering, is to provide scientists with a model that accurately mirrors dynamic fluid flow — a natural part of how lymph nodes ...

MIT Press adds Goldsmiths Press books to Direct to Open platform

2025-06-12
The MIT Press is proud to announce that it will be adding Goldsmiths Press books to its open access platform, Direct to Open (D2O), starting in 2026. The partnership expands the offerings freely available through D2O, and furthers both press’ missions in building a more open and accessible future for academic publishing. Launched in 2021, D2O is the MIT Press’s bold, innovative framework for open access monographs that shifts publishing from a solely market-based purchase model where individuals and libraries buy single ...

Turning poison into a source of energy

2025-06-12
Getting used to carbon monoxide T. kivui grows at high temperatures and is able to produce organic substances from simple molecules such as carbon dioxide and hydrogen. These properties can be used to utilize the bacterium in connection with biomass gasification plants, for example, in order to valorlize synthesis gas produced there from waste biomass such as agricultural residues or wood waste. For example, T. kivui can be used to sustainably produce acetic acid through gas fermentation and, after appropriate genetic modification, ethanol or isopropanol – raw materials ...

Towards decoding the nature of word recognition

2025-06-12
The architecture and processes underlying visual word recognition represent some of the most intricate systems in human cognition. The seemingly simple act of reading a word involves not only a complex interplay between cognitive layers but also relationships between the word’s spelling, phonology, and meaning. Over time, research has revealed that our mental systems rely on specific, consistent mappings between these properties to perform fast and accurate word recognition.   In particular, multiple studies have shown that orthographic-semantic ...

Understanding why some tumors survive heat shock treatment

2025-06-12
Since the time of the ancient Greek physician Hippocrates, cancer has been recognized as being sensitive to heat. Today, this principle forms the basis of hyperthermia treatment—a promising cancer therapy that uses controlled heat to kill tumor cells while sparing healthy ones. Unlike chemotherapy or radiation, hyperthermia works by heating cancerous tissue to temperatures around 50 °C, causing cancer cell death while simultaneously activating the body's immune system against the tumor. This approach holds particular ...

LAST 30 PRESS RELEASES:

Demystifying gut bacteria with AI

Human wellbeing on a finite planet towards 2100: new study shows humanity at a crossroads

Unlocking the hidden biodiversity of Europe’s villages

Planned hydrogen refuelling stations may lead to millions of euros in yearly losses

Planned C-sections increase the risk of certain childhood cancers

Adults who have survived childhood cancer are at increased risk of severe COVID-19

Drones reveal extreme coral mortality after bleaching

New genetic finding uncovers hidden cause of arsenic resistance in acute promyelocytic leukemia

Native habitats hold the key to the much-loved smashed avocado’s future

Using lightning to make ammonia out of thin air

Machine learning potential-driven insights into pH-dependent CO₂ reduction

Physician associates provide safe care for diagnosed patients when directly supervised by a doctor

How game-play with robots can bring out their human side

Asthma: patient expectations influence the course of the disease

UNM physician tests drug that causes nerve tissue to emit light, enabling faster, safer surgery

New study identifies EMP1 as a key driver of pancreatic cancer progression and poor prognosis

XPR1 identified as a key regulator of ovarian cancer growth through autophagy and immune evasion

Flexible, eco-friendly electronic plastic for wearable tech, sensors

Can the Large Hadron Collider snap string theory?

Stuckeman professor’s new book explores ‘socially sustainable’ architecture

Synthetic DNA nanoparticles for gene therapy

New model to find treatments for an aggressive blood cancer

Special issue of Journal of Intensive Medicine analyzes non-invasive respiratory support

T cells take aim at Chikungunya virus

Gantangqing site in southwest China yields 300,000-year-old wooden tools

Forests can’t keep up: Adaptation will lag behind climate change

Sturgeon reintroduction initiative yields promising first-year survival rate

Study: Babies’ poor vision may help organize visual brain pathways

Research reveals Arctic region was permafrost-free when global temperatures were 4.5˚ C higher than today

Novel insights into chromophobe renal cell carcinoma biology and potential therapeutic strategies

[Press-News.org] Broad-spectrum coronavirus drug developed through AI-enabled dynamic modeling
Multidisciplinary AI- and physics-driven modeling of the viral fusion process enables discovery of an orally available drug inhibiting infection with multiple coronaviruses